PMID- 35562650
OWN - NLM
STAT- MEDLINE
DCOM- 20220518
LR  - 20220716
IS  - 1471-2261 (Electronic)
IS  - 1471-2261 (Linking)
VI  - 22
IP  - 1
DP  - 2022 May 13
TI  - Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in 
      patients with heart failure with reduced ejection fraction.
PG  - 217
LID - 10.1186/s12872-022-02647-0 [doi]
LID - 217
AB  - AIMS: To evaluate the circulating levels of remodeling biomarkers procollagen 
      type 1 C-terminal propeptide (PICP), human cartilage glycoprotein-39 (YKL-40), 
      plasma renin activity (PRA), aldosterone (Aldo) as well as clinical and 
      echocardiographic parameters in patients with heart failure with reduced ejection 
      fraction (HFrEF), before and after treatment with Sacubitril/Valsartan (S/V). 
      METHODS AND RESULTS: A total of 26 consecutive patients with HFrEF on stable 
      clinical conditions were studied. Clinical, echocardiographic parameters and 
      circulating biomarkers were measured at baseline, after 30 and 60 days of S/V 
      treatment. Both systolic blood pressure (SBP) and diastolic blood pressure (DBP) 
      decreased, from 126 +/- 15 to 113 +/- 4 mmHg (p < 0.001) and from 77 +/- 11 to 
      72 +/- 9 mmHg (p = 0.005), respectively, at the end of study. Concomitantly, left 
      ventricular ejection fraction (LVEF) increased by 22.8% from 29.5 +/- 5% to 
      36.2 +/- 5%, (p < 0.001) and indexed left ventricular end-systolic volume (LVESVi) 
      decreased by 12% from 38.6 +/- 8.7 ml/m(2) to 34.0 +/- 10.0 ml/m(2). (p = 0.007). 
      Circulating levels of PICP, YKL-40, PRA and Aldo decreased by - 42.2%, - 46.8%, 
      - 79.1% and - 76.7%, respectively (p < 0.001 for all), the decrements being 
      already maximal within 30 days of S/V treatment. No significant changes of plasma 
      electrolytes and creatinine were observed during the study (all p > 0.05). 
      CONCLUSIONS: A decrease of circulating markers of inflammation and fibrosis 
      during chronic treatment with S/V is associated with an improvement of 
      hemodynamic and echographic parameters in patients with HRrEF. These data are 
      compatible with an anti-fibrotic and anti-inflammatory effect of S/V, that may 
      contribute to the beneficial outcomes of the drug in this clinical setting.
CI  - (c) 2022. The Author(s).
FAU - Bolla, Giovanni Battista
AU  - Bolla GB
AD  - Department of Clinical Sciences and Community Health, University of Milan and 
      Fondazione IRCCS Ca' GrandaOspedale Maggiore Policlinico, Milan, Italy. 
      gianni.bolla@unimi.it.
FAU - Fedele, Antonella
AU  - Fedele A
AD  - Cardiology Unit, Internal Medicine Department, Fondazione IRCCS Ca' Granda 
      Ospedale Maggiore Policlinico, Milan, Italy.
FAU - Faggiano, Andrea
AU  - Faggiano A
AD  - Cardiology Unit, Internal Medicine Department, Fondazione IRCCS Ca' Granda 
      Ospedale Maggiore Policlinico, Milan, Italy.
FAU - Sala, Carla
AU  - Sala C
AD  - Cardiology Unit, Internal Medicine Department, Fondazione IRCCS Ca' Granda 
      Ospedale Maggiore Policlinico, Milan, Italy.
FAU - Santangelo, Gloria
AU  - Santangelo G
AD  - Division of Cardiology, Department of Health Sciences, San Paolo Hospital, 
      University of Milan, Milan, Italy.
FAU - Carugo, Stefano
AU  - Carugo S
AD  - Cardiology Unit, Internal Medicine Department, Fondazione IRCCS Ca' Granda 
      Ospedale Maggiore Policlinico, Milan, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220513
PL  - England
TA  - BMC Cardiovasc Disord
JT  - BMC cardiovascular disorders
JID - 100968539
RN  - 0 (Aminobutyrates)
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Biomarkers)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Chitinase-3-Like Protein 1)
RN  - 0 (Tetrazoles)
RN  - 17ERJ0MKGI (sacubitril)
RN  - 80M03YXJ7I (Valsartan)
SB  - IM
MH  - Aminobutyrates
MH  - Angiotensin Receptor Antagonists/therapeutic use
MH  - Biomarkers
MH  - Biphenyl Compounds/therapeutic use
MH  - Chitinase-3-Like Protein 1
MH  - Fibrosis
MH  - *Heart Failure/complications/diagnosis/drug therapy
MH  - Humans
MH  - Inflammation/complications
MH  - Stroke Volume
MH  - Tetrazoles/pharmacology/therapeutic use
MH  - Valsartan/therapeutic use
MH  - *Ventricular Dysfunction, Left/complications
MH  - Ventricular Function, Left
PMC - PMC9101988
OTO - NOTNLM
OT  - Biomarkers
OT  - Fibrosis
OT  - Heart failure
OT  - Left ventricular ejection fraction
OT  - Sacubitril/Valsartan
COIS- The authors declare that they have no competing interests.
EDAT- 2022/05/14 06:00
MHDA- 2022/05/18 06:00
PMCR- 2022/05/13
CRDT- 2022/05/13 23:32
PHST- 2021/12/17 00:00 [received]
PHST- 2022/03/30 00:00 [accepted]
PHST- 2022/05/13 23:32 [entrez]
PHST- 2022/05/14 06:00 [pubmed]
PHST- 2022/05/18 06:00 [medline]
PHST- 2022/05/13 00:00 [pmc-release]
AID - 10.1186/s12872-022-02647-0 [pii]
AID - 2647 [pii]
AID - 10.1186/s12872-022-02647-0 [doi]
PST - epublish
SO  - BMC Cardiovasc Disord. 2022 May 13;22(1):217. doi: 10.1186/s12872-022-02647-0.